114 related articles for article (PubMed ID: 32239879)
21. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer].
Lü YL; Zhong M; Liu L; Wei LX; Zhao P
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
[TBL] [Abstract][Full Text] [Related]
24. Invasive ductal breast cancer molecular subtype prediction by MRI radiomic and clinical features based on machine learning.
Sheng W; Xia S; Wang Y; Yan L; Ke S; Mellisa E; Gong F; Zheng Y; Tang T
Front Oncol; 2022; 12():964605. PubMed ID: 36172153
[TBL] [Abstract][Full Text] [Related]
25. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
[TBL] [Abstract][Full Text] [Related]
26. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
27. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
28. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
29. Texture Analysis Using Semiquantitative Kinetic Parameter Maps from DCE-MRI: Preoperative Prediction of HER2 Status in Breast Cancer.
Song L; Li C; Yin J
Front Oncol; 2021; 11():675160. PubMed ID: 34168994
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HER2 gene amplification in breast cancer using nuclei microarray in situ hybridization.
Jiang H; Bai X; Zhang C; Zhang X
Int J Mol Sci; 2012; 13(5):5519-5527. PubMed ID: 22754312
[TBL] [Abstract][Full Text] [Related]
31. Integration of dynamic contrast-enhanced magnetic resonance imaging and T2-weighted imaging radiomic features by a canonical correlation analysis-based feature fusion method to predict histological grade in ductal breast carcinoma.
Fan M; Liu Z; Xie S; Xu M; Wang S; Gao X; Li L
Phys Med Biol; 2019 Oct; 64(21):215001. PubMed ID: 31470420
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
33. Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.
Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
Diagn Pathol; 2013 Feb; 8():17. PubMed ID: 23379971
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
35. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
36. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
[TBL] [Abstract][Full Text] [Related]
38. Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images.
Xue T; Chang H; Ren M; Wang H; Yang Y; Wang B; Lv L; Tang L; Fu C; Fang Q; He C; Zhu X; Zhou X; Bai Q
Sci Rep; 2023 Jun; 13(1):9746. PubMed ID: 37328516
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
[TBL] [Abstract][Full Text] [Related]
40. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
